Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1197-1207

  Kosoglou, Teddy ^a   Statkevich, Paul ^a   Fruchart, Jean Charles ^b   Pember, Laura J C ^a   Reyderman, Larisa ^a   Cutler, David L ^a   Guillaume, Michel ^c   Maxwell, Stephen E ^a   Veltri, Enrico P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Parc Eurasante Lille Metropole   (France)

^c Aster Cephac   (France)

Author keywords

Ezetimibe; Fenofibrate; Low density lipoprotein cholesterol; Pharmacodynamic; Pharmacokinetic; Triglycerides

Indexed keywords

APOLIPOPROTEIN C3; EZETIMIBE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ERUCTATION; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PARESTHESIA; PHARMACODYNAMICS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYNCOPE; TASTE DISORDER;

EID: 4344605254     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125004277     Document Type: Conference Paper

References (52)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301-7
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615-22
4. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57
7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
8. American Diabetes Association 2003. Management of dyslipidemia in adults with diabetes. Diabetes Care 26 (Suppl 1):S83-6
9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice; third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10
10. Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8
11. van Heek, M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence or absence of exocrine pancreatic function. Br. J Pharmacol 2001;134:409-17
12. Knopp RH, Gitter H, Truitt T, Lipka U, Suresh R, Veltri E. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
13. Altmann SW, Davis HR, Zhu LJ, G et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4
14. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54
15. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metabol Dispos 2002;30:430-7
16. Ezzet F, Krishna G, Wexler D, Statkevich P, Kosoglou T, Batra V. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001;23:871-85
17. Dujovne CA, Ettinger MP, McNeer F, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
18. Knopp RH, Dujovne CA, LeBeaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363-8
19. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
20. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34
21. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28
22. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24
23. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary cholesterolemia. Circulation 2003;107:2409-15
24. Physicians' Desk Reference. TRICOR™ (fenofibrate capsules, micronized) product information. Medical Economics Company: Montvale, NJ, 2001:489-92
25. Adkins JC, Faulds D. Micronized fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997;54:615-33
26. Packard CJ. Overview of fenofibrate. Eur Heart J. 1998;19(Suppl A):A62-5
27. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
28. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 11). J Am Med Assoc 1993;269:3015-23
30. Parra HJ, Mezdour H, Ghalim N, Bard J-M, Fruchart J-C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready to use plates. Clin Chem 1990;36:1431-5
31. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59-67
32. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1981;23:97-104
33. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982, p. 409-17
34. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 1987;83:50-9
35. Pearson TA. Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol. Am J Cardiol 2000;86(Suppl 1):57-61
36. Goldberg AC, Schonfeld G, Feldman EB, et al Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther 1989;11:69-83
37. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992;41:498-503
38. Frost RJA, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorrheologic parameters in Type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44-8
39. Fruchart JC, Brewer BH, and Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912-7
40. Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 2000;56:631-5
41. Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001;37(suppl A):229A [abstract]
42. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. Atherosclerosis Suppl 2001;2:89 [abstract]
43. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19
44. Knopp RH, Retzlaff B, Walden C, Fish B, Buck B, McCann B. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects (44564E). Proc Soc Exp Biol Med 2000;225:191-9
45. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999;10:561-74
46. Lussier-Cacan S, Bard JM, Boulet L, et al. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 1989;78:167-82
47. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Suppl 2001;3(Suppl E):E11-E16
48. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin Pharmacol Ther 2000;67:152
49. Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23
50. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-52
51. Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002;301:382-90
52. Keung ACF, Kosoglou T, Statkevich P, et al. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. Clin Pharmacol Ther 2001;69:P55 [abstract]